Kazia Therapeutics Limited has announced compelling preclinical and translational data for its nuclear PD-L1 degrader, NDL2. The research identifies nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression in cancer. In multiple preclinical models and patient-derived samples, NDL2 demonstrated the ability to reverse immune exhaustion, suppress metastatic behavior, and enhance anti-tumor activity, including when combined with anti-PD-1 therapy. These findings support the development of NDL2 as a first-in-class therapy that targets a limitation of current immunotherapies. Kazia plans to present additional details on the underlying biology, translational findings, and therapeutic rationale for nuclear PD-L1 degradation at an oncology-focused scientific meeting in the second quarter of 2026. First-in-human clinical trials are anticipated to begin in 2027, subject to regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN74967) on January 30, 2026, and is solely responsible for the information contained therein.